Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aerie Pharmaceuticals
A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years of age or greater (male, or female not of childbearing potential).
Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT) in the study eye(s).
Corrected visual acuity by ETDRS in each eye of +1.0 logMAR units or better
You may not be if
Known hypersensitivity to any component of the formulation or to topical anesthetics
Previous glaucoma intraocular surgery or laser procedures in study eye(s)
Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
Participation in any study involving an investigational drug within the past 30 days.
Clareo Health | Ocular Hypotensive Efficacy of AR-102
